Consensus EPS · Q1 2026
$4.31
Consensus revenue · Q1 2026
$3B
Analysts
16
Expected report
May 4, 2026
Analyst consensus (locked)
Analyst consensus
Based on estimates from 16 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $2.9B | $3B | $3.1B |
| EPS | $3.67 | $4.31 | $4.86 |
| EBITDA | $1.1B | $1.1B | $1.1B |
| EBIT | $1B | $1B | $1.1B |
| Net income | $1B | $1.1B | $1.2B |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.2B | $3.2B | +1.4% | $5.03 | $5.11 | −1.6% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Vertex Pharmaceuticals (VRTX) Q1 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 1 analyst.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $436.00 | $553.93 | $558.00 | $616.00 | $446.83 | +24.0% |
Upside calculated vs most recent trading price of $446.83.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 56 analyst ratings.
12-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 6, 2026 | Barclays | maintain | Overweight | Overweight |
| May 5, 2026 | RBC Capital | maintain | Outperform | Outperform |
| May 5, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| May 5, 2026 | Canaccord Genuity | maintain | Hold | Hold |
| May 5, 2026 | Bernstein | maintain | Outperform | Outperform |
| Apr 30, 2026 | Canaccord Genuity | maintain | Hold | Hold |
| Apr 10, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Mar 18, 2026 | Maxim Group | upgrade | Hold | Buy |
| Mar 11, 2026 | Truist Securities | maintain | Buy | Buy |
| Mar 10, 2026 | Oppenheimer | maintain | Outperform | Outperform |
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Frequently asked questions
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation